Document is current
Any future updates will be listed below
-
Authors
Tavares, Maria E. A.
Grevet, Eugenio H.
Schuch, Jaqueline B.
Temoteo, Isabella F.
Vitola, Eduardo S.
Santos, Iago J.
Ciochetti, Nicolas P. https://orcid.org/0000-0002-2922-1777
Oliveira, Victor F. https://orcid.org/0000-0003-3156-0249
Bandeira, Cibele E. https://orcid.org/0000-0003-0681-1309
Rohde, Luis A. https://orcid.org/0000-0002-4552-4188
da Silva, Bruna S. https://orcid.org/0000-0002-5916-4638
Rovaris, Diego L. https://orcid.org/0000-0002-8910-4927
Bau, Claiton H. D. https://orcid.org/0000-0001-5644-3845
- License Information
-
More Information
Article History
Received: 1 August 2025
Revised: 14 May 2026
Accepted: 12 June 2026
First Online: 8 July 2026
Competing interests
: LAR has received grant or research support from, served as a consultant to, and served on the speakers’ bureaus of Abdi Ibrahim, Abbott, Aché, Adium, Apsen, Bial, Knight Therapeutics, Medice, Novartis/Sandoz, Pfizer/ Upjohn/Viatris, and Shire/Takeda in the last 3 years. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by LAR have received unrestricted educational and research support from the following pharmaceutical companies in the last 3 years: Novartis/Sandoz and Shire/Takeda. LAR has received authorship royalties from Oxford Press and ArtMed. E.H.G. reported receiving personal fees from Takeda and EMS for lectures outside the submitted work during the 3 years prior to submission. All other authors report no biomedical financial interests or potential conflicts of interest.
: To improve the clarity and fluency of the manuscript, we used ChatGPT (OpenAI) for assistance with English grammar, punctuation, and style. The content was entirely generated by the authors, and ChatGPT was not used for data analysis, interpretation, or writing of scientific content.
